Bisphosphonate inhibits the expression of cyclin A2 at the transcriptional level in normal human oral keratinocytes

Lee,Rachel S.; Sohn,Suhjin; Shin,Ki-Hyuk; Kang,Mo K.; Park,No-Hee; Kim,Reuben H.

doi:10.3892/ijmm.2017.3066

Bisphosphonate inhibits the expression of cyclin A2 at the transcriptional level in normal human oral keratinocytes

Authors:
- Rachel S. Lee
- Suhjin Sohn
- Ki-Hyuk Shin
- Mo K. Kang
- No-Hee Park
- Reuben H. Kim
View Affiliations

Affiliations: The Shapiro Family Laboratory of Viral Oncology and Aging Research, UCLA School of Dentistry, Los Angeles, CA 90095, USA
Published online on: July 12, 2017 https://doi.org/10.3892/ijmm.2017.3066
Pages: 623-630
Copyright: © Lee et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nitrogen-containing bisphosphonates (N-BPs) are the most widely used anti-resorptive agents in the treatment of bone-related diseases. N-BPs inhibit bone resorption by specifically targeting osteoclasts, bone-resorbing cells. However, soft tissue toxicity, such as oral or gastrointestinal (GI) ulcerations has frequently been reported in N-BP users, suggesting that N-BPs may also directly target cells other than osteoclasts. Previously, we reported that BPs inhibit proliferation without inducing the apoptosis of normal human oral keratinocytes (NHOKs). However, the molecular mechanisms through which N-BPs inhibit the proliferation of NHOKs are not yet fully understood. In this study, we performed gene expression profiling in N-BP-treated NHOKs and identified cyclin A2 as one of the most commonly downregulated genes. When the NHOKs were treated with N-BPs, we found that the level of cyclin A2 was suppressed in a dose- and time-dependent manner. In addition, the protein level of cyclin A2 was also significantly lower in oral epithelial cells in N-BP-treated oral mucosal tissue constructs. Cyclin A2 promoter reporter assay revealed that N-BPs inhibited the luciferase activity, indicating that the inhibition of cyclin A2 expression occurs at the transcriptional level. Furthermore, N-BPs did not alter the expression of cyclin A2 in normal human oral fibroblasts (NHOFs), suggesting that the effect of N-BPs on cyclin A2 expression may be cell-type specific. Thus, the findings of our study demonstrate that the inhibition of NHOK proliferation by N-BPs is mediated, at least in part, by the suppression of cyclin A2 expression at the transcriptional level, which may explain the underlying mechanisms of soft tissue toxicity by N-BPs.

View Figures

View References

1	Russell RG: Bisphosphonates: The first 40 years. Bone. 49:2–19. 2011. View Article : Google Scholar : PubMed/NCBI
2	Coxon FP, Thompson K and Rogers MJ: Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol. 6:307–312. 2006. View Article : Google Scholar : PubMed/NCBI
3	Reyes C, Hitz M, Prieto-Alhambra D and Abrahamsen B: Risks and benefits of bisphosphonate therapies. J Cell Biochem. 117:20–28. 2016. View Article : Google Scholar
4	Watts N, Freedholm D and Daifotis A: The clinical tolerability profile of alendronate. Int J Clin Pract Suppl. 101:51–61. 1999.
5	Rubegni P and Fimiani M: Images in clinical medicine. Bisphosphonate-associated contact stomatitis. N Engl J Med. 355:e252006. View Article : Google Scholar : PubMed/NCBI
6	de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H and Wang KK: Esophagitis associated with the use of alendronate. N Engl J Med. 335:1016–1021. 1996. View Article : Google Scholar : PubMed/NCBI
7	Proksch E, Brandner JM and Jensen JM: The skin: An indispensable barrier. Exp Dermatol. 17:1063–1072. 2008. View Article : Google Scholar : PubMed/NCBI
8	Bae S, Sun S, Aghaloo T, Oh JE, McKenna CE, Kang MK, Shin KH, Tetradis S, Park NH and Kim RH: Development of oral osteomucosal tissue constructs in vitro and localization of fluorescently-labeled bisphosphonates to hard and soft tissue. Int J Mol Med. 34:559–563. 2014.PubMed/NCBI
9	Kim RH, Lee RS, Williams D, Bae S, Woo J, Lieberman M, Oh JE, Dong Q, Shin KH, Kang MK, et al: Bisphosphonates induce senescence in normal human oral keratinocytes. J Dent Res. 90:810–816. 2011. View Article : Google Scholar : PubMed/NCBI
10	Green JR: Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studies. Semin Oncol. 28(Suppl 6): 4–10. 2001. View Article : Google Scholar : PubMed/NCBI
11	Iguchi T, Miyakawa Y, Yamamoto K, Kizaki M and Ikeda Y: Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal. 15:719–727. 2003. View Article : Google Scholar : PubMed/NCBI
12	Horiuchi K, Umetani M, Minami T, Okayama H, Takada S, Yamamoto M, Aburatani H, Reid PC, Housman DE, Hamakubo T, et al: Wilms' tumor 1-associating protein regulates G2/M transition through stabilization of cyclin A2 mRNA. Proc Natl Acad Sci USA. 103:17278–17283. 2006. View Article : Google Scholar : PubMed/NCBI
13	Henglein B, Chenivesse X, Wang J, Eick D and Bréchot C: Structure and cell cycle-regulated transcription of the human cyclin A gene. Proc Natl Acad Sci USA. 91:5490–5494. 1994. View Article : Google Scholar : PubMed/NCBI
14	Reszka AA and Rodan GA: Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem. 4:711–719. 2004.PubMed/NCBI
15	Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA and Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 373:231–241. 2000. View Article : Google Scholar : PubMed/NCBI
16	van Beek E, Pieterman E, Cohen L, Löwik C and Papapoulos S: Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun. 255:491–494. 1999. View Article : Google Scholar : PubMed/NCBI
17	Sinensky M: Recent advances in the study of prenylated proteins. Biochim Biophys Acta. 1484:93–106. 2000. View Article : Google Scholar : PubMed/NCBI
18	Williams CL: The polybasic region of Ras and Rho family small GTPases: A regulator of protein interactions and membrane association and a site of nuclear localization signal sequences. Cell Signal. 15:1071–1080. 2003. View Article : Google Scholar : PubMed/NCBI
19	Csépányi-Kömi R, Lévay M and Ligeti E: Small G proteins and their regulators in cellular signalling. Mol Cell Endocrinol. 353:10–20. 2012. View Article : Google Scholar
20	Teramoto H, Malek RL, Behbahani B, Castellone MD, Lee NH and Gutkind JS: Identification of H-Ras, RhoA, Rac1 and Cdc42 responsive genes. Oncogene. 22:2689–2697. 2003. View Article : Google Scholar : PubMed/NCBI
21	Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N, Miki T and Gutkind JS: The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell. 81:1137–1146. 1995. View Article : Google Scholar : PubMed/NCBI
22	Hill CS, Wynne J and Treisman R: The Rho family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF. Cell. 81:1159–1170. 1995. View Article : Google Scholar : PubMed/NCBI
23	Okan E, Drewett V, Shaw PE and Jones P: The small-GTPase RalA activates transcription of the urokinase plasminogen activator receptor (uPAR) gene via an AP1-dependent mechanism. Oncogene. 20:1816–1824. 2001. View Article : Google Scholar : PubMed/NCBI
24	Mönkkönen H, Kuokkanen J, Holen I, Evans A, Lefley DV, Jauhiainen M, Auriola S and Mönkkönen J: Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs. 19:391–399. 2008. View Article : Google Scholar : PubMed/NCBI
25	Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W and van Valen F: The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro. Anticancer Drugs. 14:767–771. 2003. View Article : Google Scholar : PubMed/NCBI
26	Li YY, Chang JW, Liu YC, Wang CH, Chang HJ, Tsai MC, Su SP and Yeh KY: Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression. Anticancer Drugs. 22:89–98. 2011. View Article : Google Scholar
27	Yam CH, Fung TK and Poon RY: Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 59:1317–1326. 2002. View Article : Google Scholar : PubMed/NCBI
28	Iguchi T, Miyakawa Y, Saito K, Nakabayashi C, Nakanishi M, Saya H, Ikeda Y and Kizaki M: Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J Oncol. 31:285–291. 2007.PubMed/NCBI
29	Ory B, Blanchard F, Battaglia S, Gouin F, Rédini F and Heymann D: Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol. 71:333–343. 2007. View Article : Google Scholar